As opposed to organism-based drug screening approaches, protein-based strategies have the distinct advantage of providing insights into the molecular mechanisms of chemical effectors and thus afford a precise targeting. Capitalising on the increasing number of genome and transcriptome datasets, novel targets in pathogens for therapeutic intervention can be identified in a more rational manner when compared with conventional organism-based methodologies. Trehalose-6-phosphate phosphatases (TPPs) are structurally and functionally conserved enzymes of the trehalose biosynthesis pathway which play a critical role for pathogen survival, in particular, in parasites. The absence of these enzymes and trehalose biosynthesis from mammalian hosts has recently given rise to increasing interest in TPPs as novel therapeutic targets for drugs and vaccines. Here, we summarise some key aspects of the current state of research towards novel therapeutics targeting, in particular, nematode TPPs.
Trehalose-6-phosphate phosphatase as a broad-spectrum therapeutic target against eukaryotic and prokaryotic pathogens
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
Roberto Docampo, Megan Cross, Siji Rajan, Sonja Biberacher, Suk-Youl Park, Mark J. Coster, Ewa Długosz, Jeong-Sun Kim, Robin B. Gasser, Andreas Hofmann; Trehalose-6-phosphate phosphatase as a broad-spectrum therapeutic target against eukaryotic and prokaryotic pathogens. Emerg Top Life Sci 22 December 2017; 1 (6): 675–683. doi: https://doi.org/10.1042/ETLS20170106
Download citation file: